LPIXEL and VNPT-IT Roll Out EIRL Imaging AI on National PACS
Tokyo-based LPIXEL announced a commercial partnership with VNPT Information Technology to market its EIRL medical imaging diagnostic-support AI across Vietnam and the wider ASEAN region, after a proof-of-concept that began in September 2025 with Japan Telecommunications Engineering and Consulting Service. EIRL’s radiology analysis is being integrated into VNPT RIS/PACS, a cloud imaging platform already deployed at more than 600 Vietnamese healthcare facilities, with full clinical go-live completed at more than ten sites including Hanoi Post Hospital.
Filed under Health and dated October 1, 2026, this AI4Vietnam briefing treats the LPIXEL–VNPT-IT pact as Vietnamese clinical AI deployment news distinct from yesterday’s Viettel banking AI platforms. Workflow automation sends selected studies through a VNPT DICOM Gateway to EIRL and returns overlays to radiologists’ existing viewers; EIRL Chest Screening drew early clinician trust in the PoC, and LPIXEL said the series holds device approvals in six ASEAN markets including Vietnam.
Why it matters: Vietnamese hospitals face rising non-communicable disease imaging loads with limited radiologist density. National PACS-plus-AI can ease backlog—but only if clinical validation, liability paths and human final-read authority stay explicit.
What it means in practice
Vietnamese hospital CIOs, radiology chiefs and counsel leads should inventory which PACS sites can host EIRL-style overlays; demand named owners for DICOM Gateway security and latency SLAs; assign an owner for chest-screening false-positive review loops; run time-boxed clinical governance drills before expanding beyond pilot wards; and prefer contracts that keep radiologists on final diagnosis gates. Connect the rollout to hospital imaging-triage playbooks and Viettel’s Vietnamese legal AI agents.
Caveats come first. Ten-plus live sites are not nationwide coverage; ASEAN approvals are not automatic tender wins; and AI overlays can create automation bias. AI4Vietnam therefore presents the partnership as directional health-tech context until published outcome metrics appear.
What to watch next: expansion beyond the first ten hospitals; Thailand, Indonesia and Philippines distributor deals LPIXEL says it is seeking; and Vietnamese guidance on SaMD liability. Readers can continue on the AI4Vietnam homepage, or browse the Newsroom for additional briefings.
Bottom line: treat this update as orientation, not instruction. Vietnamese medical AI is moving from PoC into national PACS integration and remains early. Organizations that benefit most will demand clinical evidence, keep humans on final reads, and refuse to confuse a partnership announcement with finished safe automation.